HopFed Bancorp, Inc. (HFBC) At $14.80 Forms Bottom; Shorts at Arrowhead Pharmaceuticals (ARWR) Raised By 15.04%

Arrowhead Pharmaceuticals Incorporated (NASDAQ:ARWR) had an increase of 15.04% in short interest. ARWR’s SI was 4.51 million shares in February as released by FINRA. Its up 15.04% from 3.92 million shares previously. With 1.18M avg volume, 4 days are for Arrowhead Pharmaceuticals Incorporated (NASDAQ:ARWR)’s short sellers to cover ARWR’s short positions. The SI to Arrowhead Pharmaceuticals Incorporated’s float is 7.1%. The stock increased 6.58% or $0.36 during the last trading session, reaching $5.83. About 1.42 million shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since February 16, 2017 and is downtrending. It has underperformed by 83.97% the S&P500.

HopFed Bancorp, Inc. (HFBC) formed multiple bottom with $13.76 target or 7.00% below today’s $14.80 share price. HopFed Bancorp, Inc. (HFBC) has $94.48M valuation. The stock decreased 1.14% or $0.17 during the last trading session, reaching $14.8. About 62,870 shares traded or 273.05% up from the average. HopFed Bancorp, Inc. (NASDAQ:HFBC) has risen 35.45% since February 16, 2017 and is uptrending. It has outperformed by 18.75% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $505.97 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Arrowhead Research Corp had 23 analyst reports since August 5, 2015 according to SRatingsIntel. Cantor Fitzgerald initiated the shares of ARWR in report on Friday, August 19 with “Buy” rating. The rating was maintained by B. Riley & Co with “Neutral” on Monday, February 12. On Monday, November 27 the stock rating was upgraded by Piper Jaffray to “Buy”. As per Monday, February 12, the company rating was maintained by FBR Capital. Chardan Capital Markets maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Thursday, November 10 with “Buy” rating. As per Monday, November 27, the company rating was upgraded by PiperJaffray. William Blair downgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Wednesday, November 30 to “Mkt Perform” rating. The firm earned “Outperform” rating on Monday, September 18 by William Blair. The rating was maintained by Jefferies on Monday, June 26 with “Hold”. Piper Jaffray maintained the stock with “Hold” rating in Thursday, September 14 report.